Department of Radiation Oncology, Kangwon National University Hospital, Baengnyeong-ro 156, Chuncheon, 24289, Republic of Korea.
Department of Radiation Oncology, Seoul National University College of Medicine, 101 Daehangno, Jongno-gu, Seoul, 110-744, Republic of Korea.
BMC Cancer. 2017 Aug 30;17(1):598. doi: 10.1186/s12885-017-3571-3.
Treatment of tonsil cancer, a subset of oropahryngeal cancer, varies between surgery and radiotherapy. Well-designed studies in tonsil cancer have been rare and it is still controversial which treatment is optimal. This study aimed to assess the outcome and failure patterns in tonsil cancer patients treated with either approaches.
We retrospectively reviewed medical records of 586 patients with tonsil cancer, treated between 1998 and 2010 at 16 hospitals in Korea. Two hundred and one patients received radiotherapy and chemotherapy (CRT), while 385 patients received surgery followed by radiotherapy and/or chemotherapy (SRT). Compared with the SRT group, patients receiving CRT were older, with more advanced T stage and received higher radiotherapy dose given by intensity modulation techniques. Overall survival (OS), disease-free survival (DFS), locoregional recurrence-free survival (LRRFS), distant metastasis-free survival (DMFS), and clinicopathologic factors were analyzed.
At follow-up, the 5-year OS, DFS, LRRFS and DMFS rates in the CRT group were 82, 78, 89, and 94%, respectively, and in the SRT group were 81, 73, 87, and 89%, respectively. Old age, current smoking, poor performance status, advanced T stage, nodal involvement, and induction chemotherapy were associated with poor OS. Induction chemotherapy had a negative prognostic impact on OS in both treatment groups (p = 0.001 and p = 0.033 in the CRT and SRT groups, respectively).
In our multicenter, retrospective study of tonsil cancer patients, the combined use of radiotherapy and chemotherapy resulted in comparable oncologic outcome to surgery followed by postoperative radiotherapy, despite higher-risk patients having been treated with the definitive radiotherapy. Induction chemotherapy approaches combined with either surgery or definitive radiotherapy were associated with unfavorable outcomes.
扁桃体癌是口咽癌的一个亚类,其治疗方法在手术和放疗之间有所不同。在扁桃体癌中,设计良好的研究很少,哪种治疗方法最佳仍存在争议。本研究旨在评估接受这两种治疗方法的扁桃体癌患者的结局和失败模式。
我们回顾性分析了 1998 年至 2010 年期间在韩国 16 家医院接受治疗的 586 例扁桃体癌患者的病历。201 例患者接受放化疗(CRT),385 例患者接受手术加放疗和/或化疗(SRT)。与 SRT 组相比,接受 CRT 的患者年龄更大,T 分期更晚,采用调强技术给予更高的放疗剂量。分析总生存(OS)、无病生存(DFS)、局部区域无复发生存(LRRFS)、远处无转移生存(DMFS)和临床病理因素。
随访时,CRT 组的 5 年 OS、DFS、LRRFS 和 DMFS 率分别为 82%、78%、89%和 94%,SRT 组分别为 81%、73%、87%和 89%。年龄较大、当前吸烟、一般状况差、T 分期较晚、淋巴结受累和诱导化疗与 OS 不良相关。诱导化疗对两组患者的 OS 均有不良影响(CRT 组和 SRT 组 p 值分别为 0.001 和 0.033)。
在我们对扁桃体癌患者的多中心回顾性研究中,尽管对风险较高的患者采用了根治性放疗,但放疗联合化疗的综合应用与手术加术后放疗的肿瘤学结果相当。诱导化疗联合手术或根治性放疗与不良结局相关。